Adherence, Persistence, and Long-Term Success in ASCVD Lipid-Lowering Therapy

This episode, titled 'Adherence, Persistence, and Long-Term Success in ASCVD Lipid-Lowering Therapy,' features expert cardiologists discussing the significant challenge of long-term medication adherence in ASCVD management, distinguishing between adherence, meaning consistent day-to-day medication use, and persistence, meaning the sustained continuation of therapy over time. The panel identifies insurance changes and cost barriers as leading drivers of treatment discontinuation in the United States, emphasizing that clinicians must actively help patients navigate payer systems to maintain uninterrupted access to their medications. Positive reinforcement through repeat lipid panels is highlighted as a powerful motivational tool, with patients responding favorably to seeing their LDL cholesterol decline over time. One panelist shares an observation from clinical trial data showing surprisingly high adherence to a therapy requiring fasting administration, attributing this to the structured morning routine that helped patients build a consistent habit, and drawing a broader lesson that providing patients with a clear, repeatable framework for taking their medication improves long-term compliance.

The discussion then turns to the comparative adherence profiles of self-administered biweekly injectable monoclonal antibodies such as evolocumab and alirocumab versus healthcare professional-administered inclisiran given every six months, with emerging data suggesting that placing the administration responsibility on the healthcare team may support better long-term persistence. The panelists acknowledge that individual patient preferences, logistical factors such as travel distance to a clinic, insurance coverage, and the overall prescriber-patient relationship all influence which approach works best. The episode closes with a memorable analogy likening monoclonal antibody therapy to repeatedly emptying a bucket under a leaking roof, while inclisiran represents repairing the roof itself every six months, offering patients an intuitive framework for understanding why consistent adherence to their chosen therapy is essential to keeping LDL under control and reducing long-term cardiovascular risk.

In the next episode, 'Personalizing Therapy Across High-Risk Conditions and Comorbidities in ASCVD,' panelists will continue their discussion on ASCVD and highlight how clinicians can integrate non-statin therapies into practice for patients who remain above LDL goal on maximally tolerated statin therapy, while examining how comorbidities such as type 2 diabetes and chronic kidney disease inform individualized treatment selection and intensification strategies.